Amarin Corp. and Arena Pharmaceuticals were once high-flying biotech stocks. Since the commercial launch of their respective flagship products, though, their shares have fallen in a big way. In this article, I consider which stock has the better...
Amarin styled its lawsuit against the FDA looking to lift the restrictions in place on its marketing case for the prescription-strength fish oil Vascepa as a First Amendment issue regarding free speech.
Irish drugmaker Amarin, which reported another quarterly loss today, has sued the FDA for curtailing its free speech, namely being able to discuss off-label uses of its omega-3 capsule Vascepa that might spur some sales.
A confidential letter sent by top Amarin executives to doctors clearly demonstrates that the primary motive for the lawsuit the company filed yesterday against the FDA has far more to do with marketing than free speech. Amarin said it is suing the...
Amarin, which on Thursday filed a lawsuit against the Food and Drug Administration, said sales of its key drug jumped 42% in the first quarter of the year but were weighed by cold weather and healthcare plan issues.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.